Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
Presented by Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®
From West Cancer Center & Research Institute, Memphis, Tennessee
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):275–279 |
© 2020 Harborside™
Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®, reviewed optimal therapy for patients with hormone receptor–positive, HER2-negative breast cancer, as well as the management of adverse events associated with treatment.
For access to the full length article, please sign in